Replimune Group’s (REPL) “Market Perform” Rating Reiterated at Leerink Partners

Leerink Partners reissued their market perform rating on shares of Replimune Group (NASDAQ:REPL) in a report issued on Monday, MarketBeat.com reports. The firm currently has a $2.00 price target on the stock, down from their prior price target of $11.00.

Several other equities analysts also recently commented on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Replimune Group in a report on Monday. Wedbush reiterated a “neutral” rating and set a $2.00 price target (down from $19.00) on shares of Replimune Group in a report on Monday. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Friday, April 10th. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Six research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Replimune Group currently has an average rating of “Reduce” and a consensus target price of $4.75.

Replimune Group Stock Performance

Shares of NASDAQ:REPL opened at $2.28 on Monday. The company has a market capitalization of $188.26 million, a price-to-earnings ratio of -0.66 and a beta of 0.74. Replimune Group has a 12 month low of $1.50 and a 12 month high of $13.24. The firm’s 50-day moving average is $7.21 and its 200 day moving average is $7.88. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.08. Research analysts predict that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider directly owned 151,588 shares in the company, valued at $1,214,219.88. This represents a 4.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in the stock. RTW Investments LP grew its stake in Replimune Group by 11.6% in the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock worth $69,404,000 after acquiring an additional 744,620 shares in the last quarter. Fcpm Iii Services B.V. grew its stake in Replimune Group by 6.4% in the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after acquiring an additional 248,672 shares in the last quarter. State Street Corp grew its stake in Replimune Group by 26.3% in the 4th quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after acquiring an additional 768,982 shares in the last quarter. Vanguard Group Inc. grew its stake in Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after acquiring an additional 9,707 shares in the last quarter. Finally, Braidwell LP grew its stake in Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after acquiring an additional 2,327,205 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Analyst note roundup — several firms issued new/updated ratings: Leerink reaffirmed Market Perform, Jefferies reiterated Hold, and Wedbush published a Neutral. These are mostly stance-maintaining actions rather than bullish moves. Leerink Partners Reaffirms “Market Perform” Jefferies Reiterates Hold Wedbush Neutral
• Negative Sentiment: FDA rejects RP1 melanoma BLA citing trial-design concerns — the regulatory setback is the primary negative catalyst and undermines the commercial pathway/timing for RP1, prompting sharp investor selling. Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns
• Negative Sentiment: Operational impact — the company plans layoffs (63 employees) after the FDA rejection, signaling cost cuts and potential disruption to programs and morale. This amplifies downside risk to near-term execution. Mass. biotech company to lay off 63 employees after FDA rejects cancer drug for 2nd time
• Negative Sentiment: Multiple analyst downgrades and negative ratings — BMO cut to Underperform, JPMorgan to Underweight, Cantor lowered to Hold and HC Wainwright maintains a Sell. These actions increase selling pressure and reduce prospective investor demand. BMO Downgrades to Underperform JPMorgan Underweight Cantor Fitzgerald Lowers Rating HC Wainwright Reaffirms “Sell”
• Negative Sentiment: Analyst estimate cuts — HC Wainwright sharply trimmed Q1–Q4 2027 and FY2027 EPS forecasts (and lowered guidance for several quarters), reflecting expectations of greater cash burn, delayed approvals, or program setbacks; this reduces near-term valuation support. (Source: HC Wainwright research notes via market summaries)

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.